Mersana Therapeutics, Inc. announced that the FDA has granted an additional Fast Track designation for its drug XMT-1660, also known as emiltatug ledadotin (Emi-Le), aimed at treating advanced or ...

XMT-1660), Mersana’s lead Dolasynthen ADC candidate targeting B7-H4. “We believe the initial safety, tolerability and efficacy data for Emi-Le demonstrate a profile that is exciting and ...

One of the main reasons for the Buy rating is the anticipated data release for XMT-1660, which is expected to be a significant catalyst for the stock. The data, expected by the end of 2024 ...

XMT-1660 is a B7-H4-directed Dolasynthen antibody drug conjugate with a precise, target-optimized drug-to-antibody ratio (DAR 6) and Mersana’s clinically validated DolaLock microtubule inhibitor ...

On Friday, Citi initiated coverage on Mersana Therapeutics, Inc. (NASDAQ:MRSN) stock with a Buy rating and a price target of $5.00, spotlighting the potential of the company's XMT-1660 project.

Dose escalation advancing in Phase 1 clinical trials of both XMT-1660 and XMT-2056 Continue to expect to announce initial XMT-1660 clinical data and initiate expansion in the second half of 2024 ...

Its pipeline includes Emi-Le (emiltatug ledadotin; XMT-1660), a Dolasynthen ADC targeting B7-H4, and XMT-2056, an Immunosynthen ADC targeting a novel epitope of human epidermal growth factor ...

On Friday, Citi initiated coverage on Mersana Therapeutics, Inc. (NASDAQ: MRSN) stock with a Buy rating and a price target of $5.00, spotlighting the potential of the company's XMT-1660 project.The ...